Kolkata, Jun 5 : ICMR-National Institute of Cholera and Enteric Diseases (NICED), the premier research organisation under Union Ministry of Health and Family Welfare, on Friday urged the healthcare workers of the city to participate voluntarily in a regulatory trial to evaluate the efficacy of Recombinant BCG VPM 1002 in minimising infection incidence and disease severity of COVID-19 among high risk subjects. The institute is going to initiate this Central Drugs Standard Control Organisation (CDSCO) approved trial titled ‘A Multicentre, Phase III, Double-Blind, Randomised, Placebo-controlled Study’.
The study will be conducted by Dr Shanta Dutta, Director, ICMR-NICED at the institute itself at Beliaghata. The main objective of the study is to determine the effectiveness of rBCG vaccine in reducing and disease severity of COVID-19 infection among the healthcare Workers engaged in managing active COVID-19 patients.
Contacts with COVID-19 cases living in the containment zones of the city may also undergo the test. ICMR-NICED authority has requested the willing healthcare workers and others to contact Dr Suman Kanungo, with their personal details like, name, age, sex, contact numbers, working places and designation. (UNI)